Jun 17, 2020
Mesa Science Associates and Bryn Pharma Publish Final of Three Pre-Clinical Studies of a New Approach to Treating Anaphylaxis
Apr 27, 2020
Mesa Science Associates and Bryn Pharma Publish Second Pre-Clinical Study of a New Approach to Treating Anaphylaxis
Mar 23, 2020
Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migraine Following Successful End of Phase 2 Meeting with FDA
Jan 29, 2020
Dr. David Mahjoubi of Ketamine Healing Clinic Named 2020 Top Doctor by Los Angeles Magazine
Dec 09, 2019
Aptar’s Nasal Unidose Device Approved by U.S. FDA for First Nasal Rescue Treatment for Frequent Seizure Activity
Nov 20, 2019
Impel NeuroPharma Announces Publication Of Narrative Review In The Journal Headache Supporting Need For Novel Formulations Of Dihydroergotamine (DHE) In Addressing Acute Treatment Of Migraine
Nov 13, 2019
Mesa Science Associates and Bryn Pharma Announce Initial Study of a New Approach to Treating Anaphylaxis
Oct 17, 2019
Impel NeuroPharma Announces Appointment Of Diane Wilfong To Board Of Directors
Sep 05, 2019
Impel NeuroPharma to Present Data From INP104 Clinical Program at the 19th Congress of the International Headache Society
Sep 03, 2019
Satsuma Pharmaceuticals Announces Poster Presentations at the International Headache Congress
Sep 03, 2019
Impel NeuroPharma Announces Last Patient Enrolled In Phase 3 Trial Evaluating INP104 For The Treatment Of Acute Migraine
Jul 08, 2019
Satsuma Pharmaceuticals Announces Presentation of STS101 (Dihydroergotamine Nasal Powder) Phase 1 Trial Results at American Headache Society's Annual Scientific Meeting
Jun 26, 2019
FDA approves first treatment for chronic rhinosinusitis with nasal polyps
May 30, 2019
Kurve Technology Awarded Department of Defense (DOD) Contract
May 29, 2019
BlueWillow Biologics Announces Issuance of Intranasal Anthrax Vaccine Patent
Apr 30, 2019
Impel NeuroPharma To Present Data Highlighting Late-Stage Central Nervous System Pipeline At 2019 American Academy Of Neurology Meeting
Apr 01, 2019
Study Finds Vast Differences In Ease-Of-Use For Naloxone Delivery Methods
Mar 19, 2019
Aptar Pharma’s Bidose Nasal Drug Delivery Device Approved by U.S. FDA for Breakthrough Treatment of Depression
Jan 08, 2019
Dr. David Mahjoubi Of The Ketamine Healing Clinic Of L.A. Named 2019 Top Doctor By Los Angeles Magazine
Jan 07, 2019
Harebrained Approach To Treating Depression With Horse Tranquilizer Turns 10 Years Old